Preeclampsia to COVID-19: A journey towards improved placental and vascular function using sulforaphane

Placenta. 2023 Sep 26:141:84-93. doi: 10.1016/j.placenta.2023.08.063. Epub 2023 Aug 12.

Abstract

Excess inflammation and oxidative stress are common themes in many pathologies of pregnancy including preeclampsia and more recently severe COVID-19. The risk of preeclampsia increases following maternal infection with COVID-19, potentially relating to significant overlap in pathophysiology with endothelial, vascular and immunological dysfunction common to both. Identifying a therapy which addresses these injurious processes and stabilises the endothelial and vascular maternal system would help address the significant global burden of maternal and neonatal morbidity and mortality they cause. Sulforaphane is a naturally occurring phytonutrient found most densely within cruciferous vegetables. It has anti-inflammatory, antioxidant and immune modulating properties via upregulation of phase-II detoxification enzymes. This review will cover the common pathways shared by COVID-19 and preeclampsia and offer a potential therapeutic target via nuclear factor erythroid 2-related factor upregulation in the form of sulforaphane.

Publication types

  • Review

MeSH terms

  • Antioxidants / metabolism
  • Antioxidants / therapeutic use
  • COVID-19* / metabolism
  • Female
  • Humans
  • Infant, Newborn
  • Placenta / metabolism
  • Pre-Eclampsia* / metabolism
  • Pregnancy

Substances

  • sulforaphane
  • Antioxidants